The generic drug, developed by Roxane Laboratories, is intended to treat excessive daytime sleepiness and cataplexy, which causes a sudden loss of muscle control, in patients with narcolepsy.
Jazz Pharma’s shares fell 6.6 percent to $108 in after-hours trading on Tuesday in response to the approval.
More articles on suppy chain:
Pfizer CEO responds to Trump’s threats against pharma: ‘We need to raise prices’
Short seller predicts Lannett will be first drugmaker to go bankrupt amid price scrutiny
Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
